Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
Overview
Novo Nordisk (NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly (NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines that could allow them to remain ahead of their competitors in the coming years as the anti-obesity area continues to expand rapidly. But could another pharmaceutical giant eventually take the lead?
One of the more likely candidates to do so might be Roche (OTC:RHHBY), and recent developments have shown just how promising its leading candidate is. Let's find out what this could mean for investors looking to capitalize on the weight loss market.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.
Related Articles
- Stellantis CEO reconfirms 2026 guidance, says turnaround plan continues as automaker's shares hit new low
- Parents who want to help their kids in a tough job market should avoid this 1 move, says career expert
- This Warren Buffett-Recommended ETF Has Soared By 255% Over the Last 10 Years -- and History Says It Has Plenty of Room to Grow